MicroRNA-570 (miR-570), particularly miR-570-3p, has emerged as a context-dependent regulator of cancer biology with both tumor-suppressive and oncogenic functions. This review summarizes current evidence on the molecular regulation, functional roles, genetic variation, biomarker potential, and therapeutic targeting of the miR-570 network. miR-570 expression is controlled by epigenetic remodeling, DNA methylation, genomic copy-number variation, competing endogenous RNAs, and extracellular-vesicle transport. In tumor-suppressive settings, miR-570 restrains proliferation, metabolism, proteostasis, invasion, immune-checkpoint expression, stemness, treatment resistance, and metastasis through targets including DPP4, PD-L1, SPP1, IRS1/2, LCMR1, ATG12, and chaperome components. Conversely, it may promote malignancy by repressing MX2, FOXO3, PTEN, KLF9, and KLF10. These opposing effects are shaped by tumor lineage, mature strand, cellular source, target abundance, ceRNA buffering, genetic variants, and treatment state. Clinical studies suggest context-dependent diagnostic and prognostic relevance, while evidence for predictive or pharmacodynamic applications remains insufficient due to methodological heterogeneity, limited external validation, and inconsistent strand-specific measurement. Therapeutic restoration, inhibition, ceRNA targeting, and epigenetic reactivation remain promising but require molecular patient selection and precise cell-specific delivery. Future translation depends on standardized assays, direct target validation, cell-resolved profiling, and rigorous preclinical safety assessment. Accordingly, miR-570 should be viewed as a context-defined network rather than an isolated biomarker.

Introduction Emergency Departments (ED) play a central role in providing healthcare during crises such as pandemics. Evaluation of admission criteria under the circumstances of wave-dynamics is the bottleneck question for both clinical practice and planning on a structural level.Methods This study compares patient characteristics, clinical biomarkers and outcomes during wave 1 (W1) and wave 2 (W2) of the COVID-19 pandemic at two tertiary care EDs in Berlin. We validated parameters predicting hospital admission by a CART-analysis of W1 in W2 and compared the findings to a CART-model derived from W2 by a decision curve analysis.Results A total of 1,204 patients with suspected COVID-19 presented in W1 and 1,440 in W2; 106 in W1 and 722 in W2 tested positive. Patients in W2 were older (>65 years, W1: 22.2%; W2: 34.6%) and multimorbid. Mortality of positive tested (W1: 1.9%; W2:8.6%) rose in W2. The admission-predicting parameters O2 saturation <95%, dyspnea, and cardiovascular comorbidities of W1 were applicable with a sensitivity of 98.5% (CI-95%: 96.3% - 99.4%) and specificity of 68.4% (61.0%-74.9%) in W2.Conclusions Our results show transferability of admission-criteria despite changing pandemic conditions and serve as lessons learned to support future pandemic preparedness and capacity planning.

Colorectal cancer (CRC) is a biologically diverse malignancy driven by a complex interplay of genetic mutations, epigenetic changes, tumour microenvironmental factors and host-microbial interactions. Foundational molecular events including APC-associated Wnt/β-catenin dysregulation, TP53 inactivation, KRAS and BRAF mutations and aberrant PI3K/AKT signalling due to PIK3CA and PTEN alterations, contribute significantly to disease initiation, progression and therapeutic resistance. Microsatellite instability (MSI), arising from defective DNA mismatch repair, defines a distinct subset of CRC with characteristic biological and therapeutic behaviour.